Contract analysis

I. INTRODUCTION AND REQUEST FOR APPEALS CONFERENCE Penterra Pharmaceuticals Corp. ("PPC"), Employer Identification Number 22-3741856, a Delaware corporation publicly traded on the Nasdaq Stock Market under ticker symbol PPCA, hereby files this Formal Protest pursuant to the right granted by the 30-Day Letter dated November 8, 2023, the response deadline for which was extended by agreement of the parties to December 2

II. STATEMENT OF FACTS A. Penterra Pharmaceuticals Corp. — Overview PPC is a specialty pharmaceutical and biotechnology company focused on three principal therapeutic areas: oncology, immunology, and rare-disease therapeutics. The company was incorporated under the laws of the State of Delaware and maintains its corporate headquarters at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC's common

1. Penterra Pharmaceuticals Corp. ("PPC") — The ultimate parent company. Incorporated in Delaware; headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550; EIN 22-3741856.

2. Penterra Holdings Luxembourg S.à r.l. ("PHL") — A Luxembourg private limited liability company (société à responsabilité limitée), 100% owned by PPC. PHL is registered at 14, rue Aldringen, L-1118 Luxembourg, Luxembourg RCS No. B 168452. PHL is treated as a disregarded entity for U.S. federal income tax purposes and, accordingly, all of its assets, liabilities, income, and activities are attributed to PPC for U.S.

3. Penterra Biopharma International DAC ("PBI") — A Designated Activity Company organized under Irish law, 100% owned by PHL and thus indirectly 100% owned by PPC. PBI is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish Tax Reference Number is 3218764T. PBI was incorporated on March 15, 2012, and commenced operations shortly thereafter. PBI is the entity at the

4. Penterra Manufacturing Ireland Ltd. ("PMI") — An Irish private limited company, 100% owned by PBI. PMI is registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, CRO No. 512347. PMI serves as a contract manufacturer for PBI under a cost-plus arrangement (cost plus 8%), employing approximately 620 individuals at its Ringaskiddy manufacturing facility. PMI manufactures active pharmaceutical

1. CSA Cost-Sharing Ratio Adjustment: $235,010,000 The IRS proposes to increase PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year, as set forth in the following table:

2. Royalty Rate Adjustment: $188,040,000 The IRS proposes to increase the legacy IP royalty rate from 4.5% to 11.0% of net sales, resulting in additional royalty income to PPC of 6.5% of net sales for each Tax Year at Issue:

3. Correlative Offset: ($42,650,000) The IRS allowed a correlative offset of $42,650,000 to avoid double-counting between the CSA cost-sharing ratio adjustment and the royalty rate adjustment. The need for this correlative offset is itself significant, as it demonstrates the internal inconsistency of the IRS's overlapping adjustments and the imprecision of its approach. The gross proposed adjustments before the offse

4. Total Net Proposed Adjustment: $380,400,000 In addition to the foregoing adjustments, the IRS asserted that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant, arguing that key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions remained in the United States and were performed by PPC personnel. As discussed in detail in Section IV.D belo

5. Proposed Penalty: IRC § 6662(e) Substantial Valuation Misstatement Penalty The IRS proposes a 20% substantial valuation misstatement penalty under IRC § 6662(e) in the amount of approximately $15,977,000, computed as follows: $380,400,000 × 21% (weighted average effective tax rate) × 20% = approximately $15,977,000. The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h

III. APPLICABLE LAW A. IRC § 482 — Arm's-Length Standard

Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury, in any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or a

IV. ARGUMENT A. PPC's Cost-Sharing Ratios Reflect Arm's-Length Allocations and Comply with Treas. Reg. § 1.482-7

1. PBI's Cost-Sharing Percentages Are Based on Reliable Reasonably Anticipated Benefit Projections. PBI's cost-sharing percentages for the Tax Years at Issue — 38.2% (2017), 39.6% (2018), 41.1% (2019), and 42.7% (2020) — were derived from contemporaneous projections of reasonably anticipated benefits, measured by projected revenue splits between the Americas and non-Americas territories, consistent with the requireme

2. The IRS's Proposed Cost-Sharing Percentages Are Unsupported. The IRS proposes to increase PBI's cost-sharing percentages by 8 to 12 percentage points per year, from 38.2%–42.7% to 48.2%–53.7%. These proposed increases, which would result in aggregate additional cost-sharing payments of $235,010,000 over the four Tax Years at Issue, lack adequate economic foundation and are inconsistent with the arm's-length standa

3. CPM/TNMM Analysis Confirms PBI's Results Are Arm's-Length. In addition to the direct analysis of PBI's cost-sharing percentages described above, PPC has obtained an independent economic analysis that confirms the arm's-length nature of PBI's financial results under the CSA. This analysis was performed by Whitmore Valuation Group LLC, a nationally recognized independent transfer pricing and valuation firm, under th

1. CUT Analysis Supports the 4.5% Rate. PPC's 4.5% royalty rate on the Legacy IP License is supported by a CUT analysis performed by Whitmore Valuation Group LLC. Whitmore identified a set of 14 comparable uncontrolled pharmaceutical license agreements through a comprehensive search of publicly available license agreement databases, SEC filings, and proprietary transaction databases. The search criteria were designed

2. The IRS's Proposed 11.0% Rate Is Unsupported by Reliable Comparables. The IRS proposes to increase the legacy IP royalty rate from 4.5% to 11.0% of net sales, an increase of 6.5 percentage points that would result in aggregate additional royalty payments of $188,040,000 over the four Tax Years at Issue. This proposed adjustment is based on a CUT analysis prepared by IRS Economist Dr. Alan Washburne, which identifi

3. Best Method Rule Supports CUT Method with PPC's Comparables. Under the best method rule of Treasury Regulation § 1.482-1(d), the CUT method applied using the 14 Whitmore-identified comparable agreements provides the most reliable measure of an arm's-length result for the legacy IP royalty rate. The CUT method is generally regarded as the most direct and reliable method for evaluating the arm's-length nature of a r

1. Whitmore's Income Method / DCF Analysis Confirms $312M Within Range. In addition to the analyses described above, Whitmore Valuation Group LLC performed an independent valuation of the PCT payment using the income method / Discounted cash flow ("DCF") methodology. The income method is one of the specified methods for determining the arm's-length charge for a PCT under Treasury Regulation § 1.482-7(g), and is widel

2. The IRS's PCT Valuation at $852M Is Flawed. The IRS valued the PCT at $852,000,000, a delta of $540,000,000 from PPC's actual PCT payment of $312,000,000. PPC respectfully submits that the IRS's PCT valuation is materially flawed and unreliable for several reasons. First, the IRS applied an unreasonably low discount rate of 7.2% WACC, compared to the 9.8% WACC supported by Whitmore's analysis. The 2.6 percentage p